Yajie Li Joins Harbour BioMed
Harbour BioMed, a global company in the biopharmaceutical sector, is thrilled to announce the appointment of Yajie Li as Chief Medical Officer (CMO). With her extensive background in clinical development and regulatory strategy, Ms. Li is set to enhance Harbour BioMed's mission of discovering and developing groundbreaking antibody therapeutics.
Role and Responsibilities
In her new position, Ms. Li will be in charge of various critical aspects including the clinical development of the company's innovative programs and regulatory affairs. Her expertise will be pivotal as she evaluates early-stage assets by considering unmet medical needs and scientific advancements. She will report directly to Dr. Jingsong Wang, the esteemed founder and CEO of Harbour BioMed.
Expertise in the Industry
Ms. Li brings a wealth of experience accumulated over more than a decade in the pharmaceutical industry. Her impressive career includes significant contributions in clinical development and regulatory affairs at major global corporations such as Merck and Johnson & Johnson. She has also held influential positions at leading Chinese biopharmaceutical companies including GenSci and Innovent. Prior to her industry endeavors, Ms. Li served for nine years at the National Medical Products Administration of China, where she was instrumental in regulatory evaluations across diverse therapeutic areas.
Remarks from Leadership
Dr. Jingsong Wang, CEO of Harbour BioMed, expressed his enthusiasm about Ms. Li’s joining: "We are excited to integrate Yajie Li into our team, given her extensive expertise that will bolster our capacity to advance our clinical pipeline while fostering growth in our therapeutic pursuits. Her leadership is expected to pivot us toward delivering transformative medicines worldwide."
Commitment to Innovative Therapies
Yajie Li herself shared her thoughts on joining Harbour BioMed, stating that it is an honor to take on the role of CMO at such a crucial point in the company's growth. She emphasized that Harbour BioMed's advanced antibody technology platform positions it uniquely to create innovative therapies that address significant unmet medical needs. Ms. Li is eager to collaborate with her colleagues to expedite clinical development and ensure regulatory compliance, ultimately enhancing treatment accessibility for patients around the globe.
Company Overview
Harbour BioMed (HKEX: 02142) stands out as a pioneering biopharmaceutical firm heavily dedicated to the discovery of novel therapeutic antibodies especially in the fields of immunology and oncology. The company is advancing its broad pipeline through internal R&D initiatives, strategic partnerships in co-discovery and co-development, along with selective acquisitions.
At the core of its innovative efforts is Harbour BioMed's proprietary antibody technology platform known as Harbour Mice, which efficiently produces fully human monoclonal antibodies in various advanced formats. These include traditional two heavy and two light chains and the innovative heavy chain-only format. Furthermore, the integration of technologies like HBICE and HBICA enhances the development of targeted therapies with unparalleled efficacy in treating complex medical issues.
Harbour BioMed combines its state-of-the-art antibody discovery techniques, enabling it to pioneer next-generation therapeutic solutions. As they continue to progress on this promising journey, the company is dedicated to bringing impactful treatments to patients worldwide.
Frequently Asked Questions
What is Yajie Li's role at Harbour BioMed?
Yajie Li is appointed as the Chief Medical Officer, responsible for overseeing clinical development and regulatory strategy.
What is the focus of Harbour BioMed?
Harbour BioMed focuses on developing novel antibody therapeutics in immunology and oncology.
What is Harbour BioMed's notable technology platform?
The company features the Harbour Mice technology, which generates fully human monoclonal antibodies.
How did Yajie Li contribute prior to joining Harbour BioMed?
She held significant leadership roles in multinational corporations and served in the National Medical Products Administration of China.
What future developments can be anticipated from Harbour BioMed?
The company aims to accelerate clinical development, fully leveraging its advanced platform to bring new therapies to market.
